Front Cover: Development of a Tumor Microenvironment-Responsive Co(III)-Chrysin Prodrug: Synthesis, Activation Profiling, and In Vitro Antineoplastic Evaluation (ChemMedChem 20/2025)

IF 3.4 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-10-16 DOI:10.1002/cmdc.70068

Prakash Shukla, Krishna Kanta Choudhury, Kajol, Subhrata Behera, Janhabi Panigrahy, Rakesh Kumar Pathak

引用次数: 0

Abstract

The cover art illustrates the Cobalt–Chrysin Prodrug (CCP), engineered for targeted cancer therapy. On the left, cobalt(III) binds to chrysin, masking its cytotoxicity under normal conditions. The right half depicts CCP activation in the hypoxic tumor environment, releasing chrysin, which then interacts with biomolecules in cancer cells to generate reactive oxygen species (ROS) and induce apoptosis. The bright bursts symbolize selective cancer cell death, highlighting CCP′s potential as a promising anticancer therapeutic for tumor-specific destruction. More details can be found in the Research Article by Rakesh Kumar Pathak and co-workers (DOI: 10.1002/cmdc.202500232).

Abstract Image

查看原文本刊更多论文

封面：肿瘤微环境响应型Co(III)-Chrysin前药的开发：合成、激活分析和体外抗肿瘤评价（ChemMedChem 20/2025）

封面插图展示了用于靶向癌症治疗的Cobalt-Chrysin Prodrug （CCP）。在左边，钴（III）与菊花素结合，掩盖其在正常条件下的细胞毒性。右半部分描绘了CCP在低氧肿瘤环境下的激活，释放出菊花素，然后与癌细胞中的生物分子相互作用，产生活性氧（ROS）并诱导细胞凋亡。明亮的爆发象征着选择性的癌细胞死亡，突出了CCP作为一种有希望的抗癌治疗肿瘤特异性破坏的潜力。更多细节可以在Rakesh Kumar Pathak及其同事的研究文章中找到（DOI: 10.1002/cmdc.202500232）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.